← All trials
NCT04807673
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- May 31, 2023
- Completion date
- May 31, 2028
- First posted
- Mar 19, 2021
- Last posted
- Apr 1, 2021
- Enrollment
- 342
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tianjin Medical UniversityLead sponsor
- Chinese Academy of Medical SciencesCollaborator
- Fudan UniversityCollaborator
- Hebei UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Dalian Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Weifang People's HospitalCollaborator
- Shandong Jining No. 1 People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.